{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:41:20Z","timestamp":1792806080558,"version":"4.5.0"},"reference-count":65,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2023.0079","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:36:36Z","timestamp":1685954196000},"source":"Crossref","is-referenced-by-count":23,"title":["The diagnosis and treatment of osteosarcoma and Ewing\u2019s sarcoma in children and adolescents"],"prefix":"10.3238","author":[{"given":"Kourosh","family":"Zarghooni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grischa","family":"Bratke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Landgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer","family":"Eysel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"10.3238\/arztebl.m2023.0079_ref1","unstructured":"Erdmann FKP, Grabow D, Spix C: German Childhood Cancer Registry—Annual Report 2019 (1980–2018). Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University: 2020."},{"key":"10.3238\/arztebl.m2023.0079_ref2","unstructured":"(WHO) WHOCoTEB: WHO classification of tumours. Soft tissue and bone tumors. 5th edition Volume 3. International Agency for Research on Cancer. Lyon, France: WHO 2020."},{"key":"10.3238\/arztebl.m2023.0079_ref3","doi-asserted-by":"crossref","unstructured":"Esiashvili N, Goodman M, Marcus RB Jr.: Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol 2008; 30: 425–30.","DOI":"10.1097\/MPH.0b013e31816e22f3"},{"key":"10.3238\/arztebl.m2023.0079_ref4","doi-asserted-by":"crossref","unstructured":"Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776–90.","DOI":"10.1200\/JCO.2002.20.3.776"},{"key":"10.3238\/arztebl.m2023.0079_ref5","unstructured":"Le Deley MC, Delattre O, Schaefer KL, et al.: Impact of EWS-ETS fusion type on disease progression in Ewing‘s sarcoma\/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010; 28: 1982–8."},{"key":"10.3238\/arztebl.m2023.0079_ref6","unstructured":"(GPOH) GfPOuH: S1-Leitlinie Ewing-Sarkom des Kinder- und Jugendalters. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/025–006“. (last accessed on 15 May 2023)"},{"key":"10.3238\/arztebl.m2023.0079_ref7","unstructured":"(GPOH) GfPOuH: S1-Leitlinie Osteosarkome. www.awmf.org\/leitlinien\/detail\/ll\/025–005.html2021 (last accesed on 15 May 2023)."},{"key":"10.3238\/arztebl.m2023.0079_ref8","unstructured":"(DGKJ) DGfK-uJeV: S2k-Leitlinie: Muskuloskelettale Schmerzen bei Kindern und Jugendlichen—Ein Algorithmus zur differenzialdiagnostischen Abkl\u00e4rung eines h\u00e4ufigen Leitsymptoms in der Kinder- und Jugendmedizin. www.awmf.org\/uploads\/tx_szleitlinien\/027-073m_S2k_Muskuloskelettale-Schmerzen-Kinder-Jugendliche%E2%80%93Algorithmus__2020-12.pdf (last accessed on 1 March 2022)."},{"key":"10.3238\/arztebl.m2023.0079_ref9","doi-asserted-by":"crossref","unstructured":"Luedtke LM, Flynn JM, Ganley TJ, Hosalkar HS, Pill SG, Dormans JP: The orthopedists‘ perspective: bone tumors, scoliosis, and trauma. Radiol Clin North Am 2001; 39: 803–21.","DOI":"10.1016\/S0033-8389(05)70312-2"},{"key":"10.3238\/arztebl.m2023.0079_ref10","doi-asserted-by":"crossref","unstructured":"Rechl H, Kirchhoff C, Wortler K, Lenze U, Topfer A, von Eisenhart-Rothe R: [Diagnosis of malignant bone and soft tissue tumors]. Orthopade 2011; 40: 931–41; quiz 42–3.","DOI":"10.1007\/s00132-011-1821-7"},{"key":"10.3238\/arztebl.m2023.0079_ref11","doi-asserted-by":"crossref","unstructured":"Grimer RJ, Briggs TW: Earlier diagnosis of bone and soft-tissue tumours. J Bone Joint Surg Br 2010; 92: 1489–92.","DOI":"10.1302\/0301-620X.92B11.24326"},{"key":"10.3238\/arztebl.m2023.0079_ref12","doi-asserted-by":"crossref","unstructured":"Lehmann HS, Blache D, Drynan E, Tshewang P, Blignaut DJC, Musk GC: Optimum drug combinations for the sedation of growing boars prior to castration. Animals (Basel) 2017; 7: 61.","DOI":"10.3390\/ani7080061"},{"key":"10.3238\/arztebl.m2023.0079_ref13","unstructured":"Temple HT, Scully SP, Aboulafia AJ: Benign bone tumors. Instr Course Lect 2002; 51: 429–39."},{"key":"10.3238\/arztebl.m2023.0079_ref14","doi-asserted-by":"crossref","unstructured":"Yildiz C, Erler K, Atesalp AS, Basbozkurt M: Benign bone tumors in children. Curr Opin Pediatr 2003; 15: 58–67.","DOI":"10.1097\/00008480-200302000-00010"},{"key":"10.3238\/arztebl.m2023.0079_ref15","doi-asserted-by":"crossref","unstructured":"Lodwick GS, Wilson AJ, Farrell C, Virtama P, Dittrich F: Determining growth rates of focal lesions of bone from radiographs. Radiology 1980; 134: 577–83.","DOI":"10.1148\/radiology.134.3.6928321"},{"key":"10.3238\/arztebl.m2023.0079_ref16","doi-asserted-by":"crossref","unstructured":"Caracciolo JT, Temple HT, Letson GD, Kransdorf MJ: A modified lodwick-madewell grading system for the evaluation of lytic bone lesions. AJR Am J Roentgenol 2016; 207: 150–6.","DOI":"10.2214\/AJR.15.14368"},{"key":"10.3238\/arztebl.m2023.0079_ref17","doi-asserted-by":"crossref","unstructured":"Erlemann R: [MRI morphology of bone tumors and tumor-like lesions]. Radiologe 2010; 50: 61–80; quiz 1.","DOI":"10.1007\/s00117-009-1845-8"},{"key":"10.3238\/arztebl.m2023.0079_ref18","doi-asserted-by":"crossref","unstructured":"Davis JC, Daw NC, Navid F, et al.: 18F-FDG uptake during early adjuvant chemotherapy predicts histologic response in pediatric and young adult patients with osteosarcoma. J Nucl Med 2018; 59: 25–30.","DOI":"10.2967\/jnumed.117.190595"},{"key":"10.3238\/arztebl.m2023.0079_ref19","doi-asserted-by":"crossref","unstructured":"Costelloe CM, Chuang HH, Daw NC: PET\/CT of osteosarcoma and Ewing sarcoma. Semin Roentgenol 2017; 52: 255–68.","DOI":"10.1053\/j.ro.2017.04.007"},{"key":"10.3238\/arztebl.m2023.0079_ref20","doi-asserted-by":"crossref","unstructured":"Annovazzi A, Ferraresi V, Anelli V, et al.: [18F]FDG PET\/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma. Eur Radiol 2021; 31: 7012–21.","DOI":"10.1007\/s00330-021-07841-w"},{"key":"10.3238\/arztebl.m2023.0079_ref21","doi-asserted-by":"crossref","unstructured":"Leithner A, Windhager R: [Guidelines for the biopsy of bone and soft tissue tumours]. Orthopade 2007; 36: 167–74; quiz 75.","DOI":"10.1007\/s00132-006-1039-2"},{"key":"10.3238\/arztebl.m2023.0079_ref22","doi-asserted-by":"crossref","unstructured":"Bruns J, Delling G, Henne-Bruns D, Hossfeld DK: Biopsy of tumors of the musculoskeletal system. Dtsch Arztebl Int 2008; 105: 492–7.","DOI":"10.3238\/arztebl.2008.0492"},{"key":"10.3238\/arztebl.m2023.0079_ref23","unstructured":"Gemeinsamer Bundesausschuss: Richtlinie \u00fcber Ma\u00dfnahmen zur Qualit\u00e4tssicherung f\u00fcr die station\u00e4re Versorgung von Kindern und Jugendlichen mit h\u00e4mato-onkologischen Krankheiten gem\u00e4\u00df \u00a7 136 Abs. 1 Satz 1 Nr. 2 SGB V f\u00fcr nach \u00a7 108 SGB V zugelassene Krankenh\u00e4user. www.g-ba.de\/richtlinien\/47\/ (last accessed on 16 October 2022)."},{"key":"10.3238\/arztebl.m2023.0079_ref24","doi-asserted-by":"crossref","unstructured":"Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986: 9–24.","DOI":"10.1097\/00003086-198603000-00003"},{"key":"10.3238\/arztebl.m2023.0079_ref25","doi-asserted-by":"crossref","unstructured":"Kaneuchi Y, Yoshida S, Fujiwara T, Evans S, Abudu A: Limb salvage surgery has a higher complication rate than amputation but is still beneficial for patients younger than 10 years old with osteosarcoma of an extremity. J Pediatr Surg 2022: 57: 702–9.","DOI":"10.1016\/j.jpedsurg.2022.04.001"},{"key":"10.3238\/arztebl.m2023.0079_ref26","doi-asserted-by":"crossref","unstructured":"Windhager R, Funovics P, Panotopoulos J, Hobusch G, Schinhan M: [Growing prostheses after sarcoma resection in children and adolescents]. Orthopade 2019; 48: 563–71.","DOI":"10.1007\/s00132-019-03753-2"},{"key":"10.3238\/arztebl.m2023.0079_ref27","doi-asserted-by":"crossref","unstructured":"Gotta J, Bielack S, Hecker-Nolting S, et al.: When your ankle becomes a knee—long-term functional outcome and quality of life with a rotationplasty after resection of malignant limb tumors. Klin Padiatr 2022; 234: 154–62.","DOI":"10.1055\/a-1681-1916"},{"key":"10.3238\/arztebl.m2023.0079_ref28","doi-asserted-by":"crossref","unstructured":"Benady A, Gortzak Y, Sofer S, et al.: Internal hemipelvectomy for primary bone sarcomas using intraoperative patient specific instruments—the next step in limb salvage concept. BMC Musculoskelet Disord 2022; 23: 1012.","DOI":"10.1186\/s12891-022-05918-1"},{"key":"10.3238\/arztebl.m2023.0079_ref29","doi-asserted-by":"crossref","unstructured":"Dominkus M, Darwish E, Funovics P: Reconstruction of the pelvis after resection of malignant bone tumours in children and adolescents. Recent Results Cancer Res 2009; 179: 85–111.","DOI":"10.1007\/978-3-540-77960-5_8"},{"key":"10.3238\/arztebl.m2023.0079_ref30","doi-asserted-by":"crossref","unstructured":"Fujiwara T, Medellin Rincon MR, Sambri A, et al.: Limb-salvage reconstruction following resection of pelvic bone sarcomas involving the acetabulum. Bone Joint J 2021; 103-B: 795–803.","DOI":"10.1302\/0301-620X.103B4.BJJ-2020-0665.R1"},{"key":"10.3238\/arztebl.m2023.0079_ref31","doi-asserted-by":"crossref","unstructured":"Boriani S, Weinstein JN, Biagini R: Primary bone tumors of the spine. Terminology and surgical staging. Spine (Phila Pa 1976) 1997; 22: 1036–44.","DOI":"10.1097\/00007632-199705010-00020"},{"key":"10.3238\/arztebl.m2023.0079_ref32","doi-asserted-by":"crossref","unstructured":"Salzer-Kuntschik M, Delling G, Beron G, Sigmund R: Morphological grades of regression in osteosarcoma after polychemotherapy—study COSS 80. J Cancer Res Clin Oncol 1983; 106 Suppl: 21–4.","DOI":"10.1007\/BF00625047"},{"key":"10.3238\/arztebl.m2023.0079_ref33","doi-asserted-by":"crossref","unstructured":"Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C: The treatment of osteosarcoma of the extremities: twenty year‘s experience at the Istituto Ortopedico Rizzoli. Cancer 1981; 48: 1569–81.","DOI":"10.1002\/1097-0142(19811001)48:7<1569::AID-CNCR2820480717>3.0.CO;2-X"},{"key":"10.3238\/arztebl.m2023.0079_ref34","doi-asserted-by":"crossref","unstructured":"Campanacci M, Bacci G, Pagani P, Giunti A: Multiple-drug chemotherapy for the primary treatment of osteosarcoma of the extremities. J Bone Joint Surg Br 1980; 62-B: 93–101.","DOI":"10.1302\/0301-620X.62B1.6927980"},{"key":"10.3238\/arztebl.m2023.0079_ref35","unstructured":"Bielack S, Beck J, Delling G, et al.: [Neoadjuvant chemotherapy of osteosarcoma. Results of the cooperative studies COSS-80 and COSS-82 after 7 and 5 years]. Klin Padiatr 1989; 201: 275–84."},{"key":"10.3238\/arztebl.m2023.0079_ref36","doi-asserted-by":"crossref","unstructured":"Goorin AM, Perez-Atayde A, Gebhardt M, et al.: Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute\/the Children‘s Hospital--study III. J Clin Oncol 1987; 5: 1178–84.","DOI":"10.1200\/JCO.1987.5.8.1178"},{"key":"10.3238\/arztebl.m2023.0079_ref37","doi-asserted-by":"crossref","unstructured":"Purf\u00fcrst C, Beron G, Torggler S, Kotz R, Salzer-Kuntschik M, Winkler K: [Results of the COSS-77 and COSS-80 studies on adjuvant chemotherapy in osteosarcoma of the extremities]. Klin Padiatr 1985; 197: 233–8.","DOI":"10.1055\/s-2008-1033974"},{"key":"10.3238\/arztebl.m2023.0079_ref38","doi-asserted-by":"crossref","unstructured":"Winkler K, Beron G, Delling G, et al.: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329–37.","DOI":"10.1200\/JCO.1988.6.2.329"},{"key":"10.3238\/arztebl.m2023.0079_ref39","doi-asserted-by":"crossref","unstructured":"Smeland S, Bielack SS, Whelan J, et al.: Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 2019; 109: 36–50.","DOI":"10.1016\/j.ejca.2018.11.027"},{"key":"10.3238\/arztebl.m2023.0079_ref40","unstructured":"Whelan JS, Bielack SS, Marina N, et al.: EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2015; 26: 407–14."},{"key":"10.3238\/arztebl.m2023.0079_ref41","unstructured":"(GPOH) GfPOuH: S1-Leitlinie Osteosarkome. www.awmf.org\/leitlinien\/detail\/ll\/025–005.html2021“ (last accesed on 15 May 2023"},{"key":"10.3238\/arztebl.m2023.0079_ref42","unstructured":"Casali PG, Bielack S, Abecassis N, et al.: Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv79-iv95."},{"key":"10.3238\/arztebl.m2023.0079_ref43","doi-asserted-by":"crossref","unstructured":"Daw NC, Neel MD, Rao BN, et al.: Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children‘s Research Hospital OS99 trial. Cancer 2011; 117: 2770–8.","DOI":"10.1002\/cncr.25715"},{"key":"10.3238\/arztebl.m2023.0079_ref44","doi-asserted-by":"crossref","unstructured":"Marina NM, Smeland S, Bielack SS, et al.: Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 2016; 17: 1396–408.","DOI":"10.1016\/S1470-2045(16)30214-5"},{"key":"10.3238\/arztebl.m2023.0079_ref45","unstructured":"Bielack SS, Smeland S, Whelan JS, et al.: Methotrexate, Doxorubicin, and Cisplatin (MAP) plus maintenance pegylated Interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol 2015; 33: 2279–87."},{"key":"10.3238\/arztebl.m2023.0079_ref46","unstructured":"Meyers PA, Schwartz CL, Krailo MD, et al.: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children‘s Oncology Group. J Clin Oncol 2008; 26: 633–8."},{"key":"10.3238\/arztebl.m2023.0079_ref47","doi-asserted-by":"crossref","unstructured":"Grignani G, Palmerini E, Ferraresi V, et al.: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 2015; 16: 98–107.","DOI":"10.1016\/S1470-2045(14)71136-2"},{"key":"10.3238\/arztebl.m2023.0079_ref48","doi-asserted-by":"crossref","unstructured":"Grignani G, Palmerini E, Dileo P, et al.: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012; 23: 508–16.","DOI":"10.1093\/annonc\/mdr151"},{"key":"10.3238\/arztebl.m2023.0079_ref49","doi-asserted-by":"crossref","unstructured":"Duffaud F, Mir O, Boudou-Rouquette P, et al.: Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 2019; 20: 120–33.","DOI":"10.1016\/S1470-2045(18)30742-3"},{"key":"10.3238\/arztebl.m2023.0079_ref50","doi-asserted-by":"crossref","unstructured":"Davis LE, Bolejack V, Ryan CW, et al.: Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol 2019; 37: 1424–31.","DOI":"10.1200\/JCO.18.02374"},{"key":"10.3238\/arztebl.m2023.0079_ref51","doi-asserted-by":"crossref","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S, et al.: Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2020; 21: 446–55.","DOI":"10.1016\/S1470-2045(19)30825-3"},{"key":"10.3238\/arztebl.m2023.0079_ref52","doi-asserted-by":"crossref","unstructured":"Dirksen U, Brennan B, Le Deley MC, et al.: High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol 2019; 37: 3192–202.","DOI":"10.1200\/JCO.19.00915"},{"key":"10.3238\/arztebl.m2023.0079_ref53","doi-asserted-by":"crossref","unstructured":"Ladenstein R, P\u00f6tschger U, Le Deley MC, et al.: Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28: 3284–91.","DOI":"10.1200\/JCO.2009.22.9864"},{"key":"10.3238\/arztebl.m2023.0079_ref54","doi-asserted-by":"crossref","unstructured":"Le Deley MC, Paulussen M, Lewis I, et al.: Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 2014; 32: 2440–8.","DOI":"10.1200\/JCO.2013.54.4833"},{"key":"10.3238\/arztebl.m2023.0079_ref55","doi-asserted-by":"crossref","unstructured":"Paulussen M, Craft AW, Lewis I, et al.: Results of the EICESS-92 study: two randomized trials of Ewing‘s sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385–93.","DOI":"10.1200\/JCO.2008.16.5720"},{"key":"10.3238\/arztebl.m2023.0079_ref56","doi-asserted-by":"crossref","unstructured":"Grier HE, Krailo MD, Tarbell NJ, et al.: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing‘s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694–701.","DOI":"10.1056\/NEJMoa020890"},{"key":"10.3238\/arztebl.m2023.0079_ref57","doi-asserted-by":"crossref","unstructured":"Womer RB, West DC, Krailo MD, et al.: Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children‘s Oncology Group. J Clin Oncol 2012; 30: 4148–54.","DOI":"10.1200\/JCO.2011.41.5703"},{"key":"10.3238\/arztebl.m2023.0079_ref58","doi-asserted-by":"crossref","unstructured":"Anderton J, Moroz V, Marec-Berard P, et al.: International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumoursEURO EWING 2012 Protocol. Trials 2020; 21: 96.","DOI":"10.1186\/s13063-019-4026-8"},{"key":"10.3238\/arztebl.m2023.0079_ref59","unstructured":"(GPOH) GfPOuH: S1-Leitlinie Ewing-Sarkom des Kinder- und Jugendalters. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/025–006“. (last accessed on 15 May 2023)."},{"key":"10.3238\/arztebl.m2023.0079_ref60","unstructured":"Whelan J, Le Deley MC, Dirksen U, et al.: High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol 2018; 36: JCO2018782516."},{"key":"10.3238\/arztebl.m2023.0079_ref61","doi-asserted-by":"crossref","unstructured":"Foulon S, Brennan B, Gaspar N, et al.: Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. Eur J Cancer 2016; 61: 128–36.","DOI":"10.1016\/j.ejca.2016.03.075"},{"key":"10.3238\/arztebl.m2023.0079_ref62","doi-asserted-by":"crossref","unstructured":"Worawongsakul R, Steinmeier T, Lin YL, et al.: Proton therapy for primary bone malignancy of the pelvic and lumbar region—data from the prospective registries ProReg and KiProReg. Front Oncol 2022; 12: 805051.","DOI":"10.3389\/fonc.2022.805051"},{"key":"10.3238\/arztebl.m2023.0079_ref63","doi-asserted-by":"crossref","unstructured":"Kharod SM, Indelicato DJ, Rotondo RL, et al.: Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base. Pediatr Blood Cancer 2020; 67: e28080.","DOI":"10.1002\/pbc.28080"},{"key":"10.3238\/arztebl.m2023.0079_ref64","unstructured":"Meyers PA, Schwartz CL, Krailo M, et al.: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 2004–11."},{"key":"10.3238\/arztebl.m2023.0079_ref65","doi-asserted-by":"crossref","unstructured":"Brennan B, Kirton L, Marec-Berard P, et al.: Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). J Clin Oncol 2020; 38: 11500.","DOI":"10.1200\/JCO.2020.38.15_suppl.11500"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:36:50Z","timestamp":1685954210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":65,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2023.0079","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}